Open AccessPlasma anti‐ BIRC 5 IgG may be a useful marker for evaluating the prognosis of nonsmall cell lung cancer
Author(s) -
Zhao Huan,
Zhang Xuan,
Han Zhifeng,
Wang Zhenqi,
Wang Yao
Publication year - 2018
Publication title -
febs open bio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.718
H-Index - 31
ISSN - 2211-5463
DOI - 10.1002/2211-5463.12417
Subject(s) - antibody , lung cancer , malignancy , medicine , antigen , tumor marker , oncogene , stage (stratigraphy) , cancer , adenocarcinoma , immunology , oncology , cancer research , biology , cell cycle , paleontology
A recent study demonstrated that circulating levels of IgG antibodies against linear peptide antigens derived from baculoviral IAP repeat‐containing protein 5 isoform 2 ( BIRC 5) and myc proto‐oncogene protein ( MYC ) were significantly increased in nonsmall cell lung cancer ( NSCLC ). This study was undertaken to replicate this initial work in an independent sample. An enzyme‐linked immunosorbent assay ( ELISA ) was developed in‐house to examine plasma IgG antibodies for three linear peptide antigens derived from BIRC 5a, BIRC 5b, and MYC in 211 patients with NSCLC and 200 control subjects. A Mann–Whitney U ‐test demonstrated that plasma anti‐ BIRC 5a IgG levels, but not anti‐ BIRC 5b or anti‐ MYC IgG levels, were significantly higher in NSCLC patients than control subjects, especially in male patients. Both squamous cell cancer and adenocarcinoma showed increased anti‐ BIRC 5a IgG levels, but the IgG levels were not found to be changed significantly in the early stage of NSCLC . Kaplan–Meier survival analysis showed that NSCLC patients with high anti‐ BIRC 5b IgG levels had better prognosis and longer overall survival ( OS ) than patients with low anti‐ BIRC 5b IgG levels, although this significant difference failed to survive the adjustment for age, gender, NSCLC stages, and types. Plasma anti‐ BIRC 5a and MYC IgG levels did not show significant associations with OS . In conclusion, Plasma anti‐ BIRC 5 IgG may be a useful marker for assessment of prognosis of NSCLC but not for early diagnosis of this malignancy.